Daptomycin Dose Optimization in Pediatric Staphylococcus aureus Bacteremia: A Pharmacokinetic/Pharmacodynamic Investigation
The Journal of Clinical Pharmacology · 2024
DOI: 10.1002/jcph.2425 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2024. Verfasst von Katie B Olney und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY, USA. Hauptthemen laut MEDLINE: Daptomycin, Anti-Bacterial Agents, Bacteremia, Staphylococcal Infections. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Daptomycin is an antibiotic with Gram‐positive activity, including methicillin‐resistant Staphylococcus aureus , for which optimal pediatric dosing is unknown. This study aimed to evaluate daptomycin exposures achieved with package label dosing and to identify dosing regimens necessary to enhance efficacy and minimize toxicity in children with S. aureus bacteremia. Monte Carlo simulations were performed to determine probability of target attainment (PTA) for six pediatric age cohorts. Area under the curve to minimum inhibitory concentration ratio (AUC 0‐24 :MIC) ≥666 was used to determine the PTA for efficacy (PTA E ). Minimum concentration (C min ) ≥24.3 mg/L determined the PTA for toxicity (PTA T ). Acceptable dosing regimens were those which achieved the combined target of ≥90% PTA E and ≤5% PTA T . Package label dosing of daptomycin yielded insufficient efficacy with only 26.3% PTA E in children 13‐24 months, 39.5% PTA E in children 2‐6 years, 30.1% PTA E in children 7‐11 years, and 50.1% PTA E in adolescents ≥12 years. To achieve the combined efficacy and safety target, doses of 18‐24 mg/kg in children 3‐12 months, 20‐24 mg/kg in children 13‐24 months, 19‐24 mg/kg in children 2‐6 years, 17‐19 mg/kg in children 7‐11 years, and 10‐14 mg/kg in adolescents ≥12 years are necessary. Package label dosing resulted in suboptimal exposure for the majority of pediatric patients in all age groups evaluated. If targeting validated efficacy and safety endpoints, daily daptomycin doses of at least 20 mg/kg in children ≤6 years, 17 mg/kg in children 7‐11 years, and 10 mg/kg in adolescents ≥12 years are necessary. Clinical studies evaluating these higher doses are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY, USA.
- Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington, KY, USA.
- Department of Pediatrics: Division of Infectious Diseases, University of Kentucky HealthCare, Lexington, KY, USA.
- Department of Pediatrics, University of Kentucky College of Medicine, Lexington, KY, USA.
ORCID-Profile: Katie B Olney
Zitieren
APA
Olney, K. B., Howard, J. I., & Burgess, D. S. (2024). Daptomycin Dose Optimization in Pediatric Staphylococcus aureus Bacteremia: A Pharmacokinetic/Pharmacodynamic Investigation. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.2425
Vancouver
Olney KB, Howard JI, Burgess DS. Daptomycin Dose Optimization in Pediatric Staphylococcus aureus Bacteremia: A Pharmacokinetic/Pharmacodynamic Investigation. The Journal of Clinical Pharmacology. 2024. doi:10.1002/jcph.2425
BibTeX
@article{Olney2024,
author = {Olney, Katie B and Howard, Joel I and Burgess, David S},
title = {Daptomycin Dose Optimization in Pediatric Staphylococcus aureus Bacteremia: A Pharmacokinetic/Pharmacodynamic Investigation},
journal = {The Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1002/jcph.2425}
}
EUVIMED